BioPharma Bitez: GSK, Vanda, Abbvie, and more!

Happy Friday everybody!

Welcome to this week’s edition of “BioPharma Bitez”, the top news of the industry as well as one outside of it.

So, to kick it off this week, the obvious story is GSK buying Tesaro for 5 billion dollars. This will actually expand GSK’s commercial oncology portfolio. We then turn into Vanda which has a gastroparesis product candidate and phase-two clinical trials. And, if this were going to be approved, it would actually be the first treatment for gastroparesis patients within the past nearly forty years. And, they just received favorable data in that phase-two trail which is good news.

MiMedix has kept 25% of their workforce after a recent “C-suite” shake-up and purge. And, then we turn into AbbVe which has a ten billion dollar Rova-T phase-three clinical trial going on right now. And, they actually had to stop that trial after data showed that it actually shortened life-time expectancy compared to the control arm of the trial.

And then, Octillion has agreed to pay 360 million dollars to address Medicare alleged kickback allegations. Now, we’re going to turn into something outside the industry. Scientists have this week discovered a new species of salamander that they’re calling the “reticulated siren” and it was actually discovered in all places in Florida, so, if Florida was not weird enough, they now have a two-foot-long spotted snake looking with fins salamander to deal with them.

I want to thank you all again for tuning into this week’s “BioPharma Bitez.” I look forward to seeing you all next week on another edition of “BioPharma Bitez.”